Trial Profile

Adults with Acute Myeloid Leukaemia or High-Risk Myelodysplastic Syndrome (AML19): a randomised, controlled, open label Phase III trial

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 13 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cytarabine/daunorubicin (Primary) ; Ganetespib (Primary) ; Gemtuzumab ozogamicin (Primary) ; Midostaurin (Primary) ; Cytarabine; Fludarabine; Granulocyte colony-stimulating factors; Idarubicin
Indications Acute myeloid leukaemia; Acute promyelocytic leukaemia; Myelodysplastic syndromes
Focus Therapeutic Use
Acronyms AML-19

12 Dec 2023 Results assessing comprehensive genotyping and molecular MRD assessment in two consecutive prospective randomised studies (NCRI AML17 (2009-2014) and AML19 (2015-2020)) presented at the 65th American Society of Hematology Annual Meeting and Exposition.
10 Dec 2023 According to an American Society of Hematology media release, data from this study are being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight, by Jad Othman.
10 Dec 2023 Results presented in an American Society of Hematology media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com